Neuroprotective Agents

8 trials

Conditions

Mild to moderate Alzheimer'sParkinson's disease stage II-IIISTROKE Ischemic strokeSpinocerebellar AtaxiaSpinocerebellar Hereditary Ataxia Type 2mild-moderate Alzheimers diseasemild-moderate Alzheimers disease -

Phase 2

Evaluation of the neuroprotector effect of an extract of stem bark of Mangifera indica L. (Vimang®) in patient with Spinocerebellar Hereditary Ataxia Type 2

Active, not recruitingRPCEC00000005

Center of Pharmaceutical ChemistrySpinocerebellar Hereditary Ataxia Type 2

Start: 2008-03-30Target: 20Updated: 2026-10-05

NeuroEPO in stroke

Active, not recruitingRPCEC00000282

Center of Molecular Immunology (CIM)STROKE Ischemic stroke

Start: 2022-04-10Target: 130Updated: 2026-10-05

Phase 3

NeuroEPO in patients with Parkinson disease stage II-III

Active, not recruitingRPCEC00000233

Center of Molecular Immunology (CIM)Parkinson's disease stage II-III

Start: 2017-12-08Target: 102Updated: 2026-10-05

NeuroEPO in patients with Mild-Moderate Alzheimer's disease

Active, not recruitingRPCEC00000232

Center of Molecular Immunology (CIM)Mild to moderate Alzheimer's

Start: 2017-12-11Target: 174Updated: 2026-10-05

NeuroEPO-Ataxia-Adults-Phase III

Active, not recruitingRPCEC00000343

Center of Molecular Immunology (CIM)Spinocerebellar Ataxia

Start: 2021-03-01Target: 80Updated: 2026-10-05

NeuroEPO in mild-moderate Alzheimer's disease

RecruitingRPCEC00000409

Center of Molecular Immunology (CIM)mild-moderate Alzheimers disease

Start: 2023-03-20Target: 413Updated: 2026-10-05

Phase 4

NeuroEPO in mild-moderate Alzheimer's disease amnesic variant

Active, not recruitingRPCEC00000410

Center of Molecular Immunology (CIM)mild-moderate Alzheimers disease

Start: 2022-10-17Target: 1456Updated: 2026-10-05

Unknown Phase

Expanded clinical use of NeuralCIM in mild to moderate Alzheimer's disease (REAL study)

RecruitingRPCEC00000484

Center for Molecular Immunology (CIM)mild-moderate Alzheimers disease -

Start: 2026-09-14Updated: 2026-10-05

Related Papers

NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial

Alzheimer s Research & Therapy2023-12-1315 citations

The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity

Frontiers in Neuroscience2022-06-3010 citations